Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Elliott

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|April 9, 2008
Sirtuins: novel targets for metabolic diseasePeter J Elliott, Michael Jirousek
Journal of Molecular Medicine (Berlin, Germany)|April 18, 2003
Proteasome inhibition: a new anti-inflammatory strategyPeter J Elliott, Thomas Matthias Zollner, Wolf-Henning Boehncke
Nature Reviews. Drug Discovery|October 2, 2008
Sirtuins--novel therapeutic targets to treat age-associated diseasesSiva Lavu, Olivier Boss, Peter J Elliott, et al.
The Journal of Clinical Investigation|March 6, 2002
Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu modelThomas M Zollner, Maurizio Podda, Christine Pien, et al.
Annals of the New York Academy of Sciences|December 31, 2005
The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosisAlan D Brooks, Teresa Ramirez, Uhi Toh, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|December 25, 2002
Delayed treatment with MLN519 reduces infarction and associated neurologic deficit caused by focal ischemic brain injury in rats via antiinflammatory mechanisms involving nuclear factor-kappaB activation, gliosis, and leukocyte infiltrationAnthony J Williams, Sarah L Hale, John R Moffett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell linesYi-He Ling, Leonard Liebes, Jian-Dong Jiang, et al.
Nature|March 6, 2009
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activityCarles Cantó, Zachary Gerhart-Hines, Jerome N Feige, et al.
Molecular Cancer Therapeutics|December 21, 2002
PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosisYi-He Ling, Leonard Liebes, Bruce Ng, et al.
Intensive Care Medicine|December 15, 2007
The influence of corticosteroids on the release of novel biomarkers in human endotoxemiaMartijn D de Kruif, Lucienne C Lemaire, Ida A Giebelen, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Current Opinion in Investigational Drugs (London, England : 2000)|April 9, 2008
Sirtuins: novel targets for metabolic diseasePeter J Elliott, Michael Jirousek
Journal of Molecular Medicine (Berlin, Germany)|April 18, 2003
Proteasome inhibition: a new anti-inflammatory strategyPeter J Elliott, Thomas Matthias Zollner, Wolf-Henning Boehncke
Nature Reviews. Drug Discovery|October 2, 2008
Sirtuins--novel therapeutic targets to treat age-associated diseasesSiva Lavu, Olivier Boss, Peter J Elliott, et al.
The Journal of Clinical Investigation|March 6, 2002
Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu modelThomas M Zollner, Maurizio Podda, Christine Pien, et al.
Annals of the New York Academy of Sciences|December 31, 2005
The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosisAlan D Brooks, Teresa Ramirez, Uhi Toh, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|December 25, 2002
Delayed treatment with MLN519 reduces infarction and associated neurologic deficit caused by focal ischemic brain injury in rats via antiinflammatory mechanisms involving nuclear factor-kappaB activation, gliosis, and leukocyte infiltrationAnthony J Williams, Sarah L Hale, John R Moffett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell linesYi-He Ling, Leonard Liebes, Jian-Dong Jiang, et al.
Nature|March 6, 2009
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activityCarles Cantó, Zachary Gerhart-Hines, Jerome N Feige, et al.
Molecular Cancer Therapeutics|December 21, 2002
PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosisYi-He Ling, Leonard Liebes, Bruce Ng, et al.
Intensive Care Medicine|December 15, 2007
The influence of corticosteroids on the release of novel biomarkers in human endotoxemiaMartijn D de Kruif, Lucienne C Lemaire, Ida A Giebelen, et al.
Pageof 3